iBet uBet web content aggregator. Adding the entire web to your favor.
iBet uBet web content aggregator. Adding the entire web to your favor.



Link to original content: http://pubmed.ncbi.nlm.nih.gov/29728712/
[Hemorrhage under direct oral anticoagulants : Occurrence and treatment in intensive care patients] - PubMed Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 May;113(4):284-292.
doi: 10.1007/s00063-018-0436-8. Epub 2018 May 4.

[Hemorrhage under direct oral anticoagulants : Occurrence and treatment in intensive care patients]

[Article in German]
H M Hoffmeister  1 , H Darius  2 , M Buerke  3   4
Affiliations
Review

[Hemorrhage under direct oral anticoagulants : Occurrence and treatment in intensive care patients]

[Article in German]
H M Hoffmeister et al. Med Klin Intensivmed Notfmed. 2018 May.

Abstract

The use of anticoagulants is associated with an increased risk of bleeding and nevertheless bleeding complications can be lifethreatening. The focus is on bleeding under direct oral anticoagulants (DOAC) because antidotes and specific measures are lacking for some DOACs. Furthermore, routinely carried out clotting tests cannot be used to determine the degree of anticoagulation under DOACs. Therefore, it becomes difficult to determine whether the coagulation inhibition effect is present. This article presents the treatment of hemorrhage in patients with DOACs in the intensive care unit. Further, the indications for DOACS and details of administration and monitoring are presented.

Keywords: Apixaban; Blood coagulation; Blood coagulation factors; Dabigatran; Edoxaban; Hematologic agents; Rivaroxaban.

PubMed Disclaimer

Similar articles

See all similar articles

References

    1. J Thromb Haemost. 2015 Nov;13(11):2012-20 - PubMed
    1. N Engl J Med. 2016 Sep 22;375(12 ):1131-41 - PubMed
    1. Ann Intern Med. 2015 Sep 15;163(6):JC13 - PubMed
    1. Thromb Haemost. 2015 Apr;113(4):719-27 - PubMed
    1. J Am Coll Cardiol. 2017 Dec 19;70(24):3042-3067 - PubMed

LinkOut - more resources